



THE ORPHAN ONCOLOGY INNOVATOR

A French « Société anonyme » with a Board of Directors and a share capital of 11 760 851 euros
Headquarters : 49 boulevard du Général Martial Valin, 75015 Paris
410 910 095 R.C.S. Paris

ANNUAL GENERAL MEETING - APRIL 26, 2017

CORPORATE OFFICERS AND FUNCTIONS

Director	Terms of office and functions
<p>Joseph Zakrzewski</p> <p>Joseph Zakrzewski serves as Chairman of Onxeo since January 22, 2016. His term of office will expire at the General Meeting of Shareholders of 2019.</p> <p>Aged 55, Mr. Zakrzewski has over 25 years of experience in the biotechnology and the pharmaceutical industries. He is a member of the Board of Directors of several listed and unlisted companies. He advises many entities, and also engages in various philanthropic activities.</p> <p>Mr. Zakrzewski was a Venture Partner in 2010 and 2011 at Orbimed, the largest fund dedicated to health in the world. From 1988 to 2004, Mr. Zakrzewski held various positions at Eli Lilly & Company, especially in R&D, production, finance, and business development for the biotechnology and protein divisions.</p> <p><u>Business address</u> 715 Street Road, New Hope, PA 18938 Etats-Unis</p>	<p><u>Within the Company</u></p> <ul style="list-style-type: none">• Chairman of the Board of Directors of Onxeo <p><u>Outside the Company</u></p> <p>On December 31, 2016, Joseph Zakrzewski was also:</p> <ul style="list-style-type: none">• Director of Acceleron Pharmaceuticals (USA)• Director of Amarin Pharmaceuticals (USA)• Director of Insulet Corporation (USA) <p>Over the past 5 years, Joseph Zakrzewski has also performed the following functions and posts which he no longer performs:</p> <ul style="list-style-type: none">• Director of Liposcience (USA)

Director	Terms of office and functions
<p>Judith GRECIET</p> <p>Judith Greciet joined Onxeo on March 1, 2011, as Chief Operating Officer in charge of R&D and Operations. She has been Managing Director and a Director of the company since 29 June 2011. His term of office will expire at the shareholders' general meeting of 2017.</p> <p>Age 48, Judith Greciet's career has been spent in various laboratories (including Eisai, Zeneca, Wyeth), occupying important managerial and strategic international positions in the growing field of Oncology and Immunology, working on innovative products. She has a doctorate in Pharmacy and is a graduate in business administration and pharmaceutical marketing.</p> <p>Business address: ONXEO 49, Boulevard du Général Martial Valin 75015 – Paris.</p>	<p><u>Within the Company</u></p> <ul style="list-style-type: none"> • Director and Managing Director of Onxeo <p><u>Outside the Company</u></p> <p>As of December 31, 2016 Judith Greciet is also:</p> <ul style="list-style-type: none"> • President of Onxeo Inc. (United States) <p>Over the past 5 years, Judith Greciet has also performed the following functions and posts which she no longer performs:</p> <ul style="list-style-type: none"> • Chairman of Eisai France • Director of Theravectys, France • Chairman of Laboratoires BioAlliance Pharma • Director of France Biotech
<p>Russell GREIG</p> <p>Russell Greig has been a Director of Onxeo since June 26, 2013. His term of office will expire at the General Meeting of Shareholders of 2019.</p> <p>Russell Greig, 64, has over 30 years' experience in the pharmaceutical and biotech industries, with expertise in research and development and business development internationally. Russell Greig spent a significant part of his career at GlaxoSmithKline (USA/UK) where he was Senior Vice President of Worldwide Business Development R&D, President of International Pharmaceuticals and SROOne, the GSK Investment Fund.</p> <p><u>Business address</u> 1241 Karen Lane, Wayne, PA 19087-2759 United States</p>	<p><u>Within the Company</u></p> <ul style="list-style-type: none"> • Director of Onxeo <p><u>Outside the Company</u></p> <p>As of December 31, 2016, Russell Greig was also:</p> <ul style="list-style-type: none"> • Chairman of the Board of AM Pharmaceuticals (Netherlands) • Chairman of the Board of Mint Solutions (Netherlands) • Chairman of the Board of Directors of Sanifit (Spain) • Chairman of the Board of Directors of eTheRNA (Belgium) • Director of Ablynx (Belgium) • Director of TiGenix (Belgium) • Venture Partner of Kurma Partners in France <p>Over the past 5 years, Russell Greig has also performed the following functions and posts that he no longer performs:</p> <ul style="list-style-type: none"> • Chairman of the Board of Directors of Syntaxin (United Kingdom) - today Ipsen (France) • Director of Isconova (Sweden) - now Novavax AB (United States) • Chairman of the Supervisory Board of Novagali (France) - today Santen (Japan)

Director	Terms of office and functions
<p data-bbox="196 275 499 297">Danièle GUYOT-CAPARROS</p> <p data-bbox="196 338 667 461">Danièle Guyot-Caparros has been a Director of Onxeo since June 26, 2013. Her term of office will expire at the General Meeting of Shareholders of 2019.</p> <p data-bbox="196 501 667 819">Danièle Guyot-Caparros is 58. After working for an audit firm carrying out international assignments, she joined Rhône-Poulenc, later to become Aventis and then Sanofi, occupying several important posts, notably with responsibilities carried out in France at European level and then in business planning and performance monitoring on a worldwide level.</p> <p data-bbox="196 860 384 882"><u>Business address</u></p> <p data-bbox="196 891 336 981">4, rue d'Eblé 75007 Paris France</p>	<p data-bbox="699 275 922 297"><u>Within the Company</u></p> <ul data-bbox="699 309 914 331" style="list-style-type: none"> • Director of Onxeo <p data-bbox="699 376 935 398"><u>Outside the Company</u></p> <p data-bbox="699 443 1394 499">On December 31, 2016, Danièle Guyot-Caparros was also :</p> <ul data-bbox="699 510 1241 533" style="list-style-type: none"> • Member of the supervisory board of Diaxonhit
<p data-bbox="196 1066 416 1088">David H. SOLOMON</p> <p data-bbox="196 1128 667 1252">David H. Solomon has been a Director of Onxeo since June 29, 2011. His term of office will expire at the General Meeting of Shareholders of 2017.</p> <p data-bbox="196 1292 667 1610">David H. Solomon, 56, is Managing partner of Sund Capital, a fund specialized in biotechnologies and has been Chairman & Managing Director of BIONOR PHARMA (Norway). As a physician-pharmacologist, he worked for several years at Columbia University before joining Carrot Capital Healthcare Ventures, an investment firm. Since 2006, he has held various executive positions in Biotech companies.</p> <p data-bbox="196 1650 384 1673"><u>Business address</u></p> <p data-bbox="196 1682 528 1771">BionorPharma Kronprinsesse Märthas Plass 1 Vika, N-0116 Oslo, Norway</p>	<p data-bbox="699 1066 922 1088"><u>Within the Company</u></p> <ul data-bbox="699 1099 914 1122" style="list-style-type: none"> • Director of Onxeo <p data-bbox="699 1167 935 1189"><u>Outside the Company</u></p> <p data-bbox="699 1234 1302 1256">As of December 31, 2016, David H. Solomon was also a:</p> <ul data-bbox="699 1267 1385 1447" style="list-style-type: none"> • Director and Chairman of the Remuneration Committee for TxCell (France) • Director of Promosome Inc. (USA). • Director of the American Chamber of Commerce in Denmark • Director of the Cass Foundation (UK) <p data-bbox="699 1487 1394 1543">During the last five years, David H. Solomon has also held the following positions and functions that he no longer holds:</p> <ul data-bbox="699 1554 1102 1621" style="list-style-type: none"> • CEO of Zealand Pharma (Denmark) • CEO of BIONOR PHARMA (Norway)

Director	Terms of office and functions
<p>Thomas HOFSTAETTER</p> <p>Thomas Hofstaetter has been a Director of Onxeo since May 31, 2012. His term of office will expire at the General Meeting of shareholders of 2018.</p> <p>Age 78, Thomas Hofstaetter holds a doctorate in molecular biology from the University of Tübingen, Germany. He has over thirty years' experience in corporate development and mergers and acquisition of pharmaceutical and biotechnology companies, particularly with Wyeth, Inc., Aventis, VaxInnate Corporation and Geron Corporation.</p> <p><u>Business address</u> Thomas Hofstaetter Lindenstr. 37 60325 Frankfurt Germany</p>	<p><u>Within the Company</u></p> <ul style="list-style-type: none"> • Director of Onxeo <p>Over the past 5 years, Thomas Hofstaetter has also performed the following functions and posts which he no longer performs:</p> <ul style="list-style-type: none"> • Director of Bionor Pharma ASA, Norway • Director of Geron Corporation, USA • Chairman & CEO of VaxInnate Corporation, USA
<p>FINANCIERE DE LA MONTAGNE, represented by Nicolas Trebouta</p> <p>Financière de la Montagne has been a Director since June 29, 2011. Its term of office will expire at the General Meeting of Shareholders of 2017.</p> <p>Nicolas Trebouta, 53, has managed investments since 2004 directly through his company, Financière de la Montagne, or through biotech funds. Co-founder of Chevrillon and Associates in 2000, he participated via this organization in several LBO operations including Picard Surgelés, the printer CPI, and Albingia Insurance. He is a doctor and has been a shareholder of BioAlliance since 2008.</p> <p><u>Business address</u> Financière de la Montagne 4-6, Rond-Point des Champs Elysées 75008 Paris</p>	<p><u>Within the Company</u></p> <ul style="list-style-type: none"> • Director of Onxeo <p><u>Outside the Company</u></p> <p>As of 31 December 2016, Nicolas Trebouta was also:</p> <ul style="list-style-type: none"> • Manager of the SCI du Chardonnet • Manager of the SARL Financière de la Montagne SARL • Manager of the SCI Fleurus Immobilier • Manager of the SCI 5 rue de la Liberté • Chairman of the SAS Dragon 8 • Manager of the SC Financière des Associés • Director of the GIE IO • Chairman of the Supervisory Board of the SCA Chevrillon & Associés • Manager of the EARL Ferme de Bissy • Manager of the SC Valois • Manager of the SCI du Trillon • Manager of the SC Aster <p>Over the past 5 years, Nicolas Trebouta has also performed the following functions and posts which he no longer performs:</p> <ul style="list-style-type: none"> • Chairman & CEO of the SICAV Mercure Epargne Longue

Director	Terms of office and functions
<p>Jean-Pierre Bizzari</p> <p>Jean-Pierre Bizzari has been a Director since April 6, 2016. His term of office will expire at the General Meeting of Shareholders of 2019.</p> <p>Aged 63, Doctor Jean-Pierre Bizzari was Executive Vice President and Director of clinical development in Oncology for the United States, Europe, Asia and Japan for Celgene from 2008 to 2015. He participated in the clinical development of several anti-cancer agents such as Taxotere®, Eloxatin® and Abraxane®, and Irinotecan® (CPT-11). A world renowned Oncology expert, he is a member of the Scientific Advisory Council of the National Institute of Cancer (INCa), of the European Organization for Research and Treatment of Cancer (EORTC), and President of the New Drug Advisory Committee. Dr. Bizzari is also an active member of the Board of Directors of several biotechnology companies in France and the United States. He has published over 70 articles in reputable scientific journals and presented more than 160 "abstracts" at scientific congresses.</p> <p><u>Business address</u> 235 Laurel lane Haverford- PA 19041 USA</p>	<p><u>Within the Company</u> Director of Onxeo</p> <p><u>Outside the Company</u></p> <p>As of December 31, 2016, Jean-Pierre Bizzari is also:</p> <ul style="list-style-type: none"> • Director of Transgene (France) • Director of Halozyme Therapeutics (USA) • Director of Pieris Pharmaceuticals (USA) • Director of iTeos Therapeutics (Belgium) • Director of Nordic Nanovector ASA (Norway) • Director of European Organisation for Research and Treatment of Cancer (EORTC) <p>During the last five years, Jean-Pierre Bizzari has also held the following positions and functions that he no longer holds:</p> <ul style="list-style-type: none"> • Director of Celator Pharmaceuticals (USA)
<p>Jean-Pierre Kinet</p> <p>Jean-Pierre Kinet has been a Director since April 6, 2016. His term of office will expire at the General Meeting of Shareholders of 2019.</p> <p>Aged 64, the Professor and Doctor Jean-Pierre Kinet is one of the most prominent worldwide experts in Immunology, mostly known for having discovered several genes and proteins constituting the immunoglobulin E-receptors. His scientific discoveries have helped introduce therapies and new diagnostic tools for the treatment of diseases related to the deregulation of the immune system. He is also co-founder and founder of two biotechnology companies and member of the Board of Directors of several other European biotechnology companies. Dr. Kinet is Professor of Pathology at Harvard Medical School in Boston, USA. Jean-Pierre Kinet is also a member of the Scientific Advisory Committee of UCB Pharma and Managing Partner at iX Life Capital.</p> <p><u>Business address</u> 42 rue de Berri 75008 Paris France</p>	<p><u>Within the Company</u> •Director of Onxeo</p> <p><u>Outside the Company</u></p> <p>On December 31, 2016, Jean-Pierre Kinet was also:</p> <ul style="list-style-type: none"> •Director of AB Science SA (France) • Director of Pharmaleads SA (France) • Chairman of of board of directors of Vaxon SA (France) • Chairman of Ixlife Capital SAS (France) <p>During the last five years, Jean-Pierre Kinet has also held the following positions and functions that he no longer holds:</p> <ul style="list-style-type: none"> • Chairman of board of directors of Theravectys SA (France) • Director of UCB Pharma SA (Belgium)